BIOPHARMACEUTICALS

LIRAGLUTIDE

Liraglutide (API) to accelerate Diabetic therapy

Background

Liraglutide (brand name Victoza) is used as a long-acting glucagon-like peptide-1 receptor agonist to regulate insulin secretion.

• Until recently, there was no biotechnology company having a recombinant DNA- based peptide technology for Liraglutide production.
• Lorven technology on Liraglutide would benefit many pharma majors to decrease the cost of production.

Salient features Lorven’s Liraglutide

• Validated and ready-for-market
• Highly pure (96%), available at an economical price
• Expressed in our proprietary, bioengineered yeast expression system
• Direct secretion of active peptide into the growth media
• Endotoxin free secretion system
• Yields up to gm/lit/hour
• Significantly reduced production cost and time to market

Product Quality

• Our in-house Liraglutide matches with the innovator reference drug for its efficacy
• 100% native confirmation
• Free from animal-derived components

Safety

Saccharomyces: Genetically  highly  amenable  host  organism with BSL-1 maintenance.

Intellectual Property

International patent is held by Lorven Biologics Pvt. Ltd. for the bio-production of Liraglutide.
Title: Process for preparation of Liraglutide using recombinant Saccharomyces cerevisiae (WO2019082138A1)